Mrs. Salzman-Frenkel is the VP of Business Development at NeuroSense Therapeutics, spearheading all industry partnerships and investor relations.
Nedira has been in the biotech industry for over 10 years. In her last role as CEO of Salzman Group, her company raised $84M in US federal government funding.
She has founded 5 companies in the last 7 years and raised $32M in venture capital.
Mrs. Salzman-Frenkel holds a M.Sc. in Biochemistry from the Hebrew University of Jerusalem and an MBA from the Recanati School of Business at Tel Aviv University.
